Haven Capital Group, Inc. Gilead Sciences, Inc. Transaction History
Haven Capital Group, Inc.
- $113 Billion
- Q2 2025
A detailed history of Haven Capital Group, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Haven Capital Group, Inc. holds 3,987 shares of GILD stock, worth $469,867. This represents 0.39% of its overall portfolio holdings.
Number of Shares
3,987
Previous 4,310
7.49%
Holding current value
$469,867
Previous $483 Million
8.49%
% of portfolio
0.39%
Previous 0.53%
Shares
3 transactions
Others Institutions Holding GILD
# of Institutions
2,328Shares Held
1.02BCall Options Held
12.1MPut Options Held
9.13M-
Black Rock Inc. New York, NY121MShares$14.2 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.1 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.2MShares$6.98 Billion0.25% of portfolio
-
Capital World Investors Los Angeles, CA46.3MShares$5.46 Billion0.78% of portfolio
-
Wellington Management Group LLP Boston, MA37.5MShares$4.42 Billion0.79% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $148B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...